Cell-free DNA (cfDNA)
is significantly utilized for the fetal DNA screening tests to monitor the
chromosomal abnormalities, as a biomarker for the particular mutations
detection in the cancer victims, as a biomarker to detect post transplantation
rejection, and several other applications. Whereas, these are non-encapsulated
fragments of DNA molecule exists in the blood and urine that has the broad
screening and diagnostics applications. According to the Center of Disease
Control and Prevention, approximately 6,000 babies are born with the Down
disorder every year that is around 1 in every 700 babies and the syndrome
incidence is augmented by approximately 30% among 1979 and 2003. In addition,
according to the analysis by the World Health Organization, nearly 14 million
fresh cancer cases were diagnosed and are anticipated to increase by
approximately 70% over the coming 2 decades.
Not only has this, the market of cell-free DNA is
boosting owing to the developed maternal age, growing number of chronic
syndrome, transformation in the lifestyle that leads to the lifestyle syndrome
such as cancer, and the unhealthy food habits. The effective rise in the
disease incidence along with the growing medical spending and healthcare
expense deliver the opportunities for the molecular diagnostics corporates to
come up along the effective number of advancements and innovations tests in the
market. Whereas, there is a wide market place for the molecular diagnostic
corporates to enter along the novel tests directing on the transplantation
rejection cases like lung, liver and several others in the coming years.
According to the report analysis, ‘Cell-free DNA Testing Market - Global Drivers,
Restraints, Opportunities, Trends, and Forecasts: 2017-2023’
states that there are several key players which recently performing in the
Cell-free DNA market more actively for leading the fastest market growth and
dominating the high value of revenue across the globe throughout the short span
of time while significant leading the healthcare expenditure and increasing
healthcare consciousness in the underdeveloped regions and augmenting the
strategies of mergers and acquisitions includes Natera, Inc., Beijing Genomics
Institute, F. Hoffmann-La Roche (Roche), Laboratory Corporation of America
Holdings, Illumina, Inc., Guardant Health, Trovagene, Inc., Biocept, Inc., and several
other predominate & niche players.
The Global
Cell-free DNA Testing Market is predicted to observe an efficient CAGR of
26.5% during the forecast period of 2017-2023.However, the market of Cell-free
DNA is spread across the globe which extremely involves North America, Europe,
Asia Pacific, and Rest of the World (RoW). The Americas is set to be the foremost
region for the cfDNA testing market growth followed by Europe. Asia Pacific and
RoW are set to be the underdeveloped economies.
In the recent times, the cfDNA tests register the
cfDNA testing market across the globe. A lot of new players are aiming on this
market to deliver the innovative tests with great accurateness and less
turnaround time. Many foremost players in the market are establishing new
products to manage their governance in the market. Apart from this, the big
players are attaining the small companies in the market to develop their
product portfolio and manage their market leadership. For instance, in
September 2016, LabCorp assimilated Sequenom to toughen its non-invasive
prenatal testing product portfolio. Therefore, in the near years, it is
anticipated that the market of Cell-free DNA testing will increase around the
globe more positively over the coming years.
For more information on the research
report, refer to below link:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
